European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

by Minoryx Therapeutics

Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces that th...

Read more

Minoryx Therapeutics, participated by Ysios and Caixa Capital Risc, and Sperogenix Therapeutics enter into an exclusive license agreement

by Ysios Capital

Sperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...

Read more

La inversión en las startups de las ciencias de la vida y la salud en Cataluña supera por cuarto año consecutivo los 100 millones de euros

by Biocat

El “Estudio de inversión en el sector de las ciencias de la vida y la salud en Cataluña 2020” revela la buena salud del ecosistema, que casi ha igualado durante el primer semestre de 2020 el cap...

Read more

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

by Minoryx Therapeutics

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its...

Read more

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Read more

Minoryx successfully completes phase 1 clinical trial for lead candidate MIN-102

by Professional Newco

Minoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announce...

Read more

Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

by Professional Newco

MIN-102 is a selective PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept in multiple animal models. Phase I studi...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

A chip against chronic bacterial infecti...

by IBEC - Institut de Bioenginyeria de Catalunya

IBEC researchers develop a device that allows to grow biofilms and ana...

Photos Stream